Castle Biosciences, Inc.CSTL stock score: 58/100
$33.41 · +0.07% · Scored Nov 19, 2026
- Technical
- 55
- Fundamental
- 59
- News
- 51
The reading
Castle Biosciences (CSTL) scores 58 out of 100, which reads neutral, higher than 70% of Healthcare stocks and 71% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 59, technicals 55.
Among the fundamentals, Price Target at 100 and Revenue Growth (5-Year) at 100 score highest, while Earnings Growth (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 44 and contrarian oscillators 62.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 50 to 60, and it is up 1 point over the period.
About Castle Biosciences
Castle Biosciences (CSTL) is a molecular diagnostics company that develops and performs tests to help doctors guide care for patients with skin cancers, gastrointestinal disease and other conditions. Its main test, DecisionDx-Melanoma, analyzes gene expression in a patient’s tumor to estimate the risk of recurrence or spread of cutaneous melanoma and the likelihood that a sentinel lymph node biopsy would find cancer. Its other core test, TissueCypher, assesses the risk that patients with Barrett’s esophagus will progress to esophageal cancer. The company also offers a test for uveal melanoma, a cancer of the eye, and tests that help classify suspicious pigmented skin lesions. Castle earns money from payments by Medicare, commercial insurers and patients for each test report, so coverage and reimbursement decisions shape its revenue.
Castle competes with other genomic testing laboratories, academic labs and standard clinical and pathology assessment, which doctors can use instead of its tests. Its edge rests on a large body of peer-reviewed clinical evidence, Medicare coverage for its core tests and a sales force with relationships among dermatologists and gastroenterologists. Investors who follow CSTL stock tend to watch test report volumes for DecisionDx-Melanoma and TissueCypher. Average reimbursement per test and Medicare coverage decisions are closely followed. Inclusion in clinical guidelines, regulatory plans for DecisionDx-Melanoma, development of new tests, cash and operating expenses are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward CSTL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
59Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
5-year revenue growth analyzes long-term sales trajectory and consistency.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Net income growth from the prior fiscal year to the latest.
5-year earnings growth evaluates long-term profit trajectory and consistency.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
48Pulling it up
- SMA 20090
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Performance versus SPY compares the stock's returns to the S&P 500 index.
- EMA 20078
Exponential Moving Average (200-period) is a crucial long-term trend indicator that reacts faster than SMA-200.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- TRIX11
TRIX is a triple-smoothed momentum oscillator.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 44 | 1 |
| Daily | 48 | 3 |
| Weekly | 61 | 2 |
| Monthly | 63 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 58 |
| Nov 18, 2026 | 58 |
| Nov 17, 2026 | 58 |
| Nov 16, 2026 | 57 |
| Nov 15, 2026 | 58 |
| Nov 14, 2026 | 58 |
| Nov 13, 2026 | 59 |
| Nov 12, 2026 | 60 |
| Nov 11, 2026 | 53 |
| Nov 10, 2026 | 52 |
| Nov 7, 2026 | 50 |
| Nov 6, 2026 | 50 |
| Nov 5, 2026 | 52 |
| Nov 4, 2026 | 54 |
| Nov 3, 2026 | 54 |
| Nov 2, 2026 | 55 |
| Nov 1, 2026 | 56 |
| Oct 30, 2026 | 56 |
| Oct 29, 2026 | 57 |
| Oct 28, 2026 | 56 |
| Oct 27, 2026 | 56 |
| Oct 26, 2026 | 54 |
| Oct 25, 2026 | 53 |
| Oct 24, 2026 | 53 |
| Oct 23, 2026 | 53 |
| Oct 22, 2026 | 54 |
| Oct 21, 2026 | 55 |
| Oct 20, 2026 | 53 |
| Oct 19, 2026 | 52 |
| Oct 18, 2026 | 52 |
| Oct 17, 2026 | 52 |
| Oct 16, 2026 | 52 |
| Oct 15, 2026 | 54 |
| Oct 14, 2026 | 53 |
| Oct 13, 2026 | 53 |
| Oct 12, 2026 | 53 |
| Oct 11, 2026 | 55 |
| Oct 10, 2026 | 55 |
| Oct 9, 2026 | 55 |
| Oct 8, 2026 | 53 |
| Oct 7, 2026 | 53 |
| Oct 6, 2026 | 55 |
| Oct 5, 2026 | 57 |
| Oct 4, 2026 | 56 |
| Oct 3, 2026 | 56 |
| Oct 2, 2026 | 56 |
| Oct 1, 2026 | 56 |
| Sep 30, 2026 | 56 |
| Sep 29, 2026 | 55 |
| Sep 28, 2026 | 57 |
| Sep 27, 2026 | 57 |
| Sep 26, 2026 | 57 |
| Sep 25, 2026 | 57 |
| Sep 24, 2026 | 56 |
| Sep 23, 2026 | 57 |
| Sep 22, 2026 | 56 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 56 |
| Sep 19, 2026 | 56 |
| Sep 18, 2026 | 56 |
| Sep 17, 2026 | 57 |
| Sep 16, 2026 | 56 |
| Sep 15, 2026 | 57 |
| Sep 14, 2026 | 56 |
| Sep 13, 2026 | 55 |
| Sep 12, 2026 | 55 |
| Sep 11, 2026 | 55 |
| Sep 10, 2026 | 54 |
| Sep 9, 2026 | 54 |
| Sep 8, 2026 | 56 |
| Sep 7, 2026 | 55 |
| Sep 6, 2026 | 55 |
| Sep 5, 2026 | 55 |
| Sep 4, 2026 | 55 |
| Sep 2, 2026 | 56 |
| Sep 1, 2026 | 56 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 56 |
| Aug 29, 2026 | 56 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 56 |
| Aug 26, 2026 | 56 |
| Aug 25, 2026 | 57 |
| Aug 24, 2026 | 56 |
| Aug 23, 2026 | 57 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Beta
- 0.95
- Risk grade (1–10)
- 6
- Next earnings
- Nov 5, 2026
Diagnostics & Research peers
| Company | Market cap | Score |
|---|---|---|
| CDNA CareDx | $3.8B | 59 |
| VCYT Veracyte | $2.0B | 64 |
| NEO NeoGenomics | $2.0B | 51 |
| PSNL Personalis | $1.6B | 45 |
| WGS GeneDx Holdings | $1.5B | 50 |
| OPK OPKO Health | $1.2B | 33 |
Questions
What is CSTL's stock rating today?
CSTL scores 58/100 (Neutral) as of Nov 19, 2026: technical 55, fundamental 59, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does Castle Biosciences do?
Castle Biosciences (CSTL) is a molecular diagnostics company that develops and performs tests to help doctors guide care for patients with skin cancers, gastrointestinal disease and other conditions. Its main test, DecisionDx-Melanoma, analyzes gene expression in a patient’s tumor to estimate the risk of recurrence or spread of cutaneous melanoma and the likelihood that a sentinel lymph node biopsy would find cancer.
Is CSTL stock a buy?
The score is not a buy or sell recommendation. A 58 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the CSTL score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/cstl/"><img src="https://stocksscores.com/stocks/cstl/badge.svg" alt="CSTL stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/cstl/)